Law Offices of Howard G. Smith announces that it is investigating potential claims on behalf of investors of Amarin Corporation plc (“Amarin” or the “Company”) (NASDAQ:AMRN) concerning possible violations of federal securities laws. The investigation focuses on certain statements issued by the Company concerning Amarin’s business, operations and financial prospects.
Amarin is a biopharmaceutical company, focused on the development and commercialization therapeutic products for the treatment for cardiovascular diseases. The Company’s lead product, Vascepa, is as an adjunct to diet to reduce triglyceride levels in adult patients and also for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol (the “Anchor” indication).
The investigation is related to allegations that the Company misrepresented the prospects for Food and Drug Administration marketing approval of Vascepa for the Anchor indication, and also failed to disclose that the FDA had informed Amarin that there was a lack of prospective, controlled clinical trial data demonstrating that pharmaceutical reduction of triglycerides significantly reduces residual cardiovascular risk.
If you purchased Amarin shares, if you have information or would like to learn more about these claims, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, Toll Free at (888) 638-4847, or by email to email@example.com, or visit our website at www.howardsmithlaw.com.